Group 1 - The board of directors of Yunnan Energy Investment Co., Ltd. held its second regular meeting for 2025 on August 20, 2025, with all 9 directors present, complying with the Company Law and the Articles of Association [1] - The meeting approved the "2025 Half-Year Report and its Summary" with 9 votes in favor, 0 against, and 0 abstentions [1] - The financial information in the "2025 Half-Year Report" has been reviewed and approved by the company's audit committee [2] Group 2 - The board also approved the "Special Report on the Management and Use of Raised Funds for the First Half of 2025" with the same voting results [3] - The "Shareholder Dividend Return Plan for the Next Three Years (2025-2027)" was approved and will be submitted to the shareholders' meeting for further review [3] - The specific date for the shareholders' meeting will be announced later [3]

证券代码：688128 证券简称：中国电研 公告编号：2025-029 中国电器科学研究院股份有限公司 第二届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 中国电器科学研究院股份有限公司（以下简称"公司"）第二届监事会第九 次会议于 2025 年 8 月 21 日下午在广州市海珠区新港西路 204 号第 1 栋以现场、 视频结合的方式召开，本次会议通知及相关材料已于 2025 年 8 月 11 日以电子邮 件方式送达公司全体监事。本次会议由监事会主席周寅伦先生主持，会议应到监 事三人，实到监事三人，公司副总经理、董事会秘书王柳女士及审计部工作人员 列席了会议。本次会议的召集、召开符合《中华人民共和国公司法》和《公司章 程》的有关规定。 二、 监事会会议审议情况 公司监事会认为：公司 2025 年半年度募集资金存放、管理与实际使用情况 符合《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司 自律监管指引第 1 号——规范运作》及公司《募集资金管理办法》等法 ...

（四）对闲置募集资金进行现金管理，投资相关产品情况 公司于 2024 年 8 月 27 日召开了第二届董事会第十次会议和第二届监事会第 十次会议，审议通过了《关于公司使用部分暂时闲置募集资金进行现金管理的议 案》，同意公司在确保不影响募集资金安全和投资项目资金使用进度安排的前提 下，使用不超过 8.7 亿元（含本数）的暂时闲置募集资金进行现金管理，用于购 买安全性高、流动性好的保本型产品，在上述额度范围内，资金可以滚动使用， 使用期限不超过 12 个月，自 2024 年 9 月 1 日起至 2025 年 8 月 31 日止。具体内 容详见公司于 2024 年 8 月 28 日刊登在上海证券交易所网站(www.sse.com.cn)的 《普冉半导体（上海）股份有限公司关于使用部分暂时闲置募集资金进行现金管 理的公告》（公告编号：2024-049）。 截 至 2025 年 6 月 30 日 ， 公 司 已 使 用 闲 置 募 集 资 金 进 行 现 金 管 理 行现金管理的授权额度，具体如下： 证券代码：688766 证券简称：普冉股份 公告编号：2025-056 普冉半导体（上海）股份有限公司 本公司董事会及全 ...

Fundraising Overview - The company raised a total of RMB 939.5 million by issuing 50 million shares at RMB 18.79 per share, with the funds deposited in designated bank accounts [1][2] - As of June 30, 2025, the company has used RMB 725.48 million of the raised funds, with RMB 248.30 million for working capital and RMB 477.18 million for project investments [2][3] Fund Management - The company established a fundraising management method in 2019, which was revised in 2022 to ensure strict compliance with fund storage, usage, and supervision [3][4] - A tripartite supervision agreement was signed with banks to manage the special fundraising accounts [4][5] Fund Usage and Investment - As of June 30, 2025, the company had a remaining balance of RMB 98.39 million in its fundraising accounts, with total interest income of RMB 50.96 million [2][3] - The company has engaged in cash management for idle funds, investing in structured deposits with varying interest rates, achieving returns of 1.95% to 2.15% [5][6] Project Funding and Adjustments - The company has made adjustments to its project funding, including the addition of new project entities and locations, and has allocated RMB 18.77 million to a new project, the Manufacturing Service Innovation Base [5][7] - The company has not experienced any significant changes in project feasibility during the reporting period [7][8] Compliance and Reporting - The company has ensured that all disclosed information regarding the management and usage of raised funds is timely, truthful, accurate, and complete, with no violations in fund management [7][8]

Fundraising Overview - The company raised a total of RMB 507.204 million through its initial public offering, with a net amount of RMB 446.0052 million after deducting issuance costs [1] - As of June 30, 2025, the company has utilized RMB 370.913 million of the raised funds for various projects, including RMB 265.069 million for the Dapeng Drone Manufacturing Base Project and RMB 60.702 million for the R&D Center Construction Project [1][2] Fund Management - The company has established a fundraising management system to ensure the effective use of raised funds, which are stored in a special account approved by the board of directors [1][2] - A tripartite supervision agreement has been signed with the sponsor and the bank managing the funds to ensure compliance with regulations [1][2] Project Adjustments - The company approved adjustments to the internal investment structure of the R&D Center Construction Project, extending the implementation period and adding Chengdu Zongheng Yunlong Drone Technology Co., Ltd. as an implementation entity [2][3] - The company will provide interest-free loans to its wholly-owned subsidiaries to support the implementation of fundraising projects [1][2] Cash Management - The company has approved the temporary use of idle raised funds, not exceeding RMB 50 million, to supplement working capital for business expansion and daily operations [3] - The company has also approved the use of idle funds for cash management, allowing investments in safe and liquid financial products up to RMB 32 million [3][4]

Core Viewpoint - The announcement provides a detailed report on the fundraising activities of Sanxiang New Materials Co., Ltd. for the first half of 2025, including the amount raised, its usage, and management practices, ensuring compliance with regulatory requirements [1][2][3]. Fundraising Basic Situation - The company raised a total of RMB 220 million by issuing 11.0664 million shares at RMB 19.88 per share, with a net amount of RMB 216.0763 million after deducting issuance costs of RMB 3.9236 million [1]. - As of December 31, 2024, the cumulative amount directly invested from the raised funds was RMB 155.2413 million, leaving a balance of RMB 63.1313 million, which includes RMB 60.8351 million in raised funds and interest income of RMB 0.22962 million [2]. Fundraising Management Situation - The company has established a fundraising management system to ensure the proper use and storage of raised funds, protecting investor interests [2][3]. - Funds are stored in dedicated accounts with three banks, and a tripartite supervision agreement has been signed to ensure strict approval processes for fund usage [3]. Actual Use of Fundraising - The actual use of the raised funds in the first half of 2025 amounted to RMB 6.0175 million, with no prior investments or replacements reported [7]. - The company has temporarily used RMB 56.6207 million of idle funds to supplement working capital, with a board resolution allowing for the use of up to RMB 75 million for this purpose [7][8]. - No idle funds have been used for cash management or investment in financial products as of June 30, 2025 [8]. Changes in Fundraising Investment Projects - There have been no changes in the use of funds for investment projects as of June 30, 2025 [8]. Issues in Fundraising Usage and Disclosure - The company has complied with regulations regarding the timely and accurate disclosure of the storage and usage of raised funds [8].

证券代码：600882 证券简称：妙可蓝多 公告编号：2025-076 上海妙可蓝多食品科技股份有限公司 的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海妙可蓝多食品科技股份有限公司（以下简称"公司"）董事会根据中 国证券监督管理委员会（以下简称"中国证监会"）发布的《上市公司募集资 金监管规则》及上海证券交易所发布的《上海证券交易所上市公司自律监管指 引第 1 号—规范运作》《上海证券交易所上市公司自律监管指南第 1 号—公告 格式》等相关规定，现将公司 2025 年半年度募集资金存放、管理与实际使用情 况专项报告如下： 一、募集资金基本情况 经中国证监会出具的《关于核准上海妙可蓝多食品科技股份有限公司非公 开发行股票的批复》（证监许可[2021]1466 号）核准，公司向内蒙古蒙牛乳业 （集团）股份有限公司非公开发行 A 股股票 100,976,102 股，每股发行价格为 人民币 29.71 元。本次非公开发行募集资金总额为人民币 2,999,999,990.42 元， 扣除不含税各项发行费用人民币 18, ...

Core Points - The document outlines the fundraising management system of Chengdu Zongheng Automation Technology Co., Ltd, aiming to regulate the management and utilization of raised funds, enhance efficiency, and protect investors' rights [1][2]. Fundraising Management - The company must establish internal control systems for the storage, management, use, and supervision of raised funds, including approval authority and disclosure requirements [2][3]. - Raised funds must be deposited in a special account approved by the board of directors, and the number of accounts should not exceed the number of fundraising projects [3][4]. - The company is required to sign a tripartite supervision agreement with the sponsor or independent financial advisor and the commercial bank within one month of the funds being received [4][5]. Fund Utilization - Funds should be used according to the investment plan outlined in the issuance application documents, ensuring transparency and compliance with national policies [5][6]. - If significant changes occur in the market environment or if the project is delayed, the company must reassess the feasibility and disclose the situation [6][7]. - The company is prohibited from using raised funds for financial investments or to benefit related parties improperly [6][8]. Supervision and Reporting - The company must disclose the actual use of raised funds accurately and timely, especially if there are significant deviations from the investment plan [16][17]. - The board of directors is responsible for monitoring the management and use of raised funds and must prepare and disclose a special report on the funds' status [17][18]. - Independent financial advisors must conduct regular audits and report any irregularities to the relevant authorities [18][19].

第二条 本制度所称募集资金是指公司通过公开发行证券（包括首次公开发 行股票、配股、增发、发行可转换公司债券、发行分离交易的可转换公司债券 等）以及非公开发行证券向投资者募集的资金，但不包括公司实施股权激励计划 募集的资金。 第三条 公司董事会应当对募集资金投资项目的可行性进行充分论证，确信 投资项目具有较好的市场前景和盈利能力，有效防范投资风险，提高募集资金使 用效益。 三祥新材股份有限公司 募集资金使用管理制度 第一章 总则 第一条 为了规范三祥新材股份有限公司(以下简称"公司")募集资金的管 理，提高募集资金使用效率，根据《中华人民共和国公司法》《中华人民共和国 证券法》《上市公司募集资金监管规则》《上海证券交易所股票上市规则》《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》等相关法律、法规和 规范性文件的规定，结合公司实际情况，制定本制度。 第四条 公司的董事和高级管理人员应当勤勉尽责，督促公司规范使用募集 资金，自觉维护公司募集资金安全，不得参与、协助或纵容公司擅自或变相改变 募集资金用途。 第五条 公司董事会应根据《公司法》《证券法》《上海证券交易所股票上 市规则》等有关法律法规的规定 ...

东方证券股份有限公司 关于浙江华康药业股份有限公司部分募集资金投资项目终止 并将剩余募集资金永久补充流动资金及注销募集资金专户 的核查意见 东方证券股份有限公司（以下简称"东方证券"或"保荐机构"）作为浙江 华康药业股份有限公司（以下简称"华康股份"或"公司"）首次公开发行股票 并上市的持续督导机构及向不特定对象发行可转换公司债券的保荐机构，根据 《证券发行上市保荐业务管理办法》《上市公司募集资金监管规则》（以下简称 "《监管规则》"）《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》（以下简称"《规范运作》"）、《上海证券交易所股票上市规则》（以下 简称"《上市规则》"）等法律法规，对华康股份部分募集资金投资项目终止并 将剩余募集资金永久补充流动资金及注销募集资金专户的事项进行了核查，核查 情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准浙江华康药业股份有限公司首次公开 发行股票的批复》（证监许可[2020]3152 号）核准并经上海证券交易所同意，公 司首次公开发行人民币普通股 A 股股票 2,914 万股，每股发行价格为人民币 51.63 元，募集资金总额为人民币 150 ...